Compare Cassava Sciences Inc (FLNA) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs ProShares Ultra QQQ ETF — how do they compare? Cassava Sciences Inc trades at $0.84 (market cap $39.40M), while ProShares Ultra QQQ ETF trades at $98.22 (market cap $15.38B). The key difference: ProShares Ultra QQQ ETF is far larger — about 390.4× Cassava Sciences Inc's market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and ProShares Ultra QQQ ETF for 37 Days on average.
| FLNA | QLD | |
|---|---|---|
Market Cap | $39.40M | $15.38B |
Volume | 759,018 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $100.77 |
52-Week Low | $0.68 | $57.16 |
Typical Hold Time | 37 Days | 37 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
QLD (ProShares Ultra QQQ ETF) trades at $98.12, down 2.11% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum while oscillators remain neutral. The ETF benefits from 2x leverage on the Nasdaq-100, providing amplified exposure to large-cap tech stocks. Recent institutional buying and media coverage highlight continued investor interest in leveraged tech exposure.
Outlook remains cautiously optimistic given the bullish technical setup and institutional accumulation, though leveraged ETFs carry elevated volatility risks during market downturns. The key opportunity lies in continued tech sector strength, while the primary risk involves amplified losses if the Nasdaq-100 declines significantly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
